Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 28, 2015, Pages 8738-8743

  Pascal, Kristen E ^a   Coleman, Christopher M ^b   Mujica, Alejandro O ^a   Kamat, Vishal ^a   Badithe, Ashok ^a   Fairhurst, Jeanette ^a   Hunt, Charleen ^a   Strein, John ^a   Berrebi, Alexander ^b   Sisk, Jeanne M ^b   Matthews, Krystal L ^b   Babb, Robert ^a   Chen, Gang ^a   Lai, Ka Man V ^a   Huang, Tammy T ^a   Olson, William ^a   Yancopoulos, George D ^a   Stahl, Neil ^a   Frieman, Matthew B ^b   Kyratsous, Christos A ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

DPP4; MERS CoV; Mouse model; Neutralizing antibody; Spike

Indexed keywords

ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE IV; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; REGN 3048; REGN 3051; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CHO CELL LINE; CONTROLLED STUDY; CORONAVIRUS INFECTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; HISTOPATHOLOGY; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; MOUSE MODEL; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; ANIMAL; CORONAVIRUS INFECTIONS; DISEASE MODEL; HEK293 CELL LINE; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

ANIMALIA; CORONAVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 84937107017     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1510830112     Document Type: Article

References (42)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814-1820.
2. Coleman CM, Frieman MB (2013) Emergence of the Middle East respiratory syndrome coronavirus. PLoS Pathog 9(9):e1003595.
3. Assiri A, et al.; KSA MERS-CoV Investigation Team (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369(5):407-416.
4. Cotten M, et al. (2014) Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio 5(1):e01062-13.
5. Perlman S, McCray PB, Jr (2013) Person-to-person spread of the MERS coronavirus - An evolving picture. N Engl J Med 369(5):466-467.
6. Meyer B, et al. (2014) Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 20(4):552-559.
7. Perera RA, et al. (2013) Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 18(36):20574.
8. Reusken CB, et al. (2013) Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: A comparative serological study. Lancet Infect Dis 13(10):859-866.
9. Masters PS (2006) The molecular biology of coronaviruses. Adv Virus Res 66:193-292.
10. Gierer S, et al. (2013) The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87(10):5502-5511.
11. Raj VS, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251-254.
12. Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF (2000) A guardian angel: The involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci (Lond) 99(2):93-104.
13. Lu G, et al. (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227-231.
14. Wang N, et al. (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23(8):986-983.
15. Falzarano D, et al. (2013) Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19(10):1313-1317.
16. Dyall J, et al. (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885-4893.
17. Adedeji AO, et al. (2014) Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses. Antimicrob Agents Chemother 58(8):4894-4898.
18. de Wilde AH, et al. (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58(8):4875-4884.
19. Du L, et al. (2013) A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: Implication for developing therapeutics and vaccines. PLoS ONE 8(12):e81587.
20. Coleman CM, et al. (2014) Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32(26):3169-3174.
21. Zhao J, et al. (2014) Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 111(13):4970-4975.
22. Falzarano D, et al. (2014) Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 10(8):e1004250.
23. Agrawal AS, et al. (2015) Generation of transgenic mouse model of Middle East respiratory syndrome-coronavirus infection and disease. J Virol 89(7):3659-3670.
24. Smith EC, Blanc H, Vignuzzi M, Denison MR (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathog 9(8):e1003565.
25. Rockx B, et al. (2010) Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201(6):946-955.
26. Ying T, et al. (2014) Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J Virol 88(14):7796-7805.
27. Tang X-C, et al. (2014) Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 111(19):E2018-E2026.
28. Malpica JM, et al. (2002) The rate and character of spontaneous mutation in an RNA virus. Genetics 162(4):1505-1511.
29. Smith EC, Denison MR (2013) Coronaviruses as DNA wannabes: A new model for the regulation of RNA virus replication fidelity. PLoS Pathog 9(12):e1003760.
30. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol 81(22):12135-12144.
31. Cotten M, et al. (2013) Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study. Lancet 382(9909):1993-2002.
32. Jiang L, et al. (2014) Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 6(234):234ra59.
33. Coleman CM, Matthews KL, Goicochea L, Frieman MB (2014) Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 95(Pt 2):408-412.
34. Cockrell AS, et al. (2014) Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol 88(9):5195-5199.
35. Good RA, Lorenz E (1991) Historic aspects of intravenous immunoglobulin therapy. Cancer 68(6, Suppl):1415-1421.
36. Marasco WA, Sui J (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25(12):1421-1434.
37. Murphy AJ, et al. (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 111(14):5153-5158.
38. Macdonald LE, et al. (2014) Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA 111(14):5147-5152.
39. Wang X, Stollar BD (2000) Human immunoglobulin variable region gene analysis by single cell RT-PCR. J Immunol Methods 244(1-2):217-225.
40. Page C, et al. (2012) Induction of alternatively activated macrophages enhances pathogenesis during severe acute respiratory syndrome coronavirus infection. J Virol 86(24):13334-13349.
41. Valenzuela DM, et al. (2003) High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 21(6):652-659.
42. Poueymirou WT, et al. (2007) F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. Nat Biotechnol 25(1):91-99.